Investigating B Cells in Membranous Nephropathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients with membranous nephropathy (MN), a leading cause of nephrotic syndrome in adults. It aims to analyze the role of autoreactive B-cells in patients who respond to B-cell depleting therapy with anti-CD20 monoclonal antibodies compared to those who do not. By examining the differences in B- and T-cell compartments, the study seeks to understand why some patients achieve remission while others do not. The research involves in vitro assays to explore these cellular dynamics.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients inclusion criteria

* Males and females.
* Adults (\> 18 years old).
* Patients with biopsy-proven idiopathic MN, who are candidate to receive (prospective cohort) or who already received (retrospective cohort) a B-cell depleting treatment as per center clinical practice.
* Mental state is such that they are able to understand and give valid consent to the study;
* Written informed consent according to the guidelines of the Declaration of Helsinki.

Healthy volunteers inclusion criteria

* Male and female (\>18 years) not known to suffer of any significant illness;
* Not assuming any medication or drug on a regular basis;
* Negative urine analysis (urine dipstick, multistick);
* Written informed consent according to the guidelines of the Declaration of Helsinki

Exclusion Criteria:

Patients exclusion criteria

* Reasonable possibility of a secondary cause of MN (e.g.systemic lupus erythematosus, active hepatitis B, malignancy, drugs such as gold salts and penicillamine).
* Legal incapacity, intellectual disability/mental retardation, dementia, uncooperative attitude or any other evidence that patient will not be able to understand the study procedures and aims and to give written informed consent.

Healthy volunteers exclusion criteria

\- Legal incapacity, intellectual disability/mental retardation, dementia, uncooperative attitude or any other evidence that patient will not be able to understand the study procedures and aims and to give written informed consent.

Where it's running

• Centro di Ricerche Cliniche per le Malattie Rare " Aldo e Cele Daccò"
  Ranica, Bg, Italy Recruiting

Study contacts

• Study coordinator: Manuel Podestà, MD
• Email: manuel.podesta@guest.marionegri.it
• Phone: 003903545351

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rituximab plus Cyclosporine for Primary Membranous Nephropathy

  This study tests whether adding Cyclosporine to Rituximab helps people with primary membranous nephropathy achieve remission of heavy protein in the urine faster.

  Recruiting Phase 2/3 Peking University First Hospital · Beijing · NCT07861204

• HLX79 with rituximab (HLX01) for active glomerulonephritis

  This trial will test whether adding HLX79 at different doses to rituximab (HLX01) helps adults with active membranous nephropathy or lupus nephritis.

  Recruiting Phase 2 Shanghai Henlius Biotech · Beijing and 16 other locations · NCT07038382

• Using Raman Spectroscopy to Diagnose Kidney Diseases

  This study is testing a new way to diagnose kidney diseases by analyzing urine and blood samples from patients with specific kidney conditions to see if it can help identify the diseases more accurately.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT06760845

• Testing ManNAc for treating kidney disease FSGS

  This study is testing if a new oral treatment called ManNAc can help adults with kidney disease FSGS by reducing protein levels in their urine and checking how safe it is over 12 weeks.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06664814

• AI-guided personalized rituximab for membranous nephropathy

  This trial will test whether an AI-guided approach to dosing rituximab improves remission in adults with PLA2R1-positive nephrotic membranous nephropathy.

  Recruiting at 13 sites Phase 3 Centre Hospitalier Universitaire de Nice · Besançon and 13 other locations · NCT06341205

• Long-term outcomes in primary membranous nephropathy

  This project will follow adults with primary membranous nephropathy and nephrotic syndrome to see how their disease and real-world treatments affect long-term kidney outcomes.

  Recruiting Mario Negri Institute for Pharmacological Research · Bergamo, BG and 1 other locations · NCT06242327

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.